A Phase I, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Aldafermin in Subjects With Impaired Hepatic Function
Latest Information Update: 29 Dec 2022
At a glance
- Drugs Aldafermin (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors NGM Biopharmaceuticals
Most Recent Events
- 08 Nov 2022 Results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
- 15 Jan 2022 Status changed from recruiting to completed.
- 07 Apr 2021 New trial record